Spatial Genomics & Transcriptomics Market by Product (Instruments, Consumables, Services), Technique(Transcriptomics (IHC, ISH), Genomics (LCM)), Service Type(Sample Prep, Sequencing), Application (Translation Research (Cancer))-Global Forecast to 2029
세계의 공간 유전체학·전사체학 제품 시장 규모는 2024년 5억 5,450만 달러에서 2029년까지 9억 9,570만 달러에 달할 것으로 예측되며, 예측 기간에 CAGR로 12.4%의 성장이 전망됩니다.
| 조사 범위 |
| 조사 대상연도 |
2022-2029년 |
| 기준연도 |
2023년 |
| 예측 기간 |
2024-2029년 |
| 단위 |
달러 |
| 부문 |
제공, 기법, 용도, 유형(서비스), 최종사용자(제품), 최종사용자(서비스) |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 |
공간유전체-트랜스스크립틱스 시장은 신제품의 도입과 신약개발 및 의약품 개발에서 공간유전체-트랜스스크립틱스의 수용 확대 등의 요인에 영향을 받아 성장하고 있습니다. 하지만 고가의 초기 자본 투입, 기술적 복잡성, 지식 격차 등이 산업계에 다양한 어려움을 야기하고 있습니다.
"제품별로는 제품 부문이 2023년 시장에서 가장 큰 점유율을 차지했습니다."
제품 부문이 2023년 가장 큰 점유율을 차지했습니다. 연구 분야에서 고해상도 공간 유전자 및 단백질 발현 데이터에 대한 수요 증가가 이 부문의 성장을 설명하는 데 도움이 될 것입니다. 시장 확대의 주요 촉진요인은 제약 연구 및 개발에서 소모품 및 공간 유전체학/트랜스스크립틱스의 적용 확대와 바이오마케터 발굴이 주요 성장 요인으로 꼽힙니다. 이 시장 부문의 주요 성장 촉진요인은 시장 진출기업이 특히 공간 분석 및 신제품 도입을 위한 다양한 소프트웨어 개발에 대한 투자를 늘리고 있다는 점입니다.
"기술별로는 공간 트랜스크립션 기법이 22023년 가장 높은 시장 점유율을 차지했습니다."
in situ 시퀀싱 기술의 수용이 확대되고 질병 연구에 보다 종합적으로 활용됨에 따라 공간 전사체학 부문은 2023년 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다. 공간 전사체학을 통해 조직의 공간적 맥락에서 유전자 발현을 매핑할 수 있습니다. 조직학 및 분자 데이터를 결합하여 특정 조직 영역에서 유전자가 어떻게 발현되는지 밝혀내어 세포 조직, 기능, 질병 진행에 대한 이해를 돕습니다.
"아시아태평양은 2024-2029년 시장에서 가장 높은 CAGR로 성장할 것입니다."
아시아태평양은 의료 수요 증가에 대한 정부 활동 증가, 생명공학에 대한 정부 투자 증가, 정밀의료에 대한 수요 증가, 의료비 증가, 인도, 중국, 일본 등 주요 시장에서의 연구개발 확대, 양호한 규제 환경으로 인해 가장 빠르게 성장하는 시장이 될 것으로 예상됩니다. 될 것으로 추정됩니다. 한편, 북미는 2023년에 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
세계의 공간유전체학-트랜스스크립틱스(Space Genomics-Transcriptomics) 시장을 조사 분석했으며, 주요 촉진요인과 저해요인, 경쟁 구도, 향후 동향 등의 정보를 전해드립니다.
목차
제1장 서론
제2장 조사 기법
제3장 개요
제4장 주요 인사이트
- 공간 유전체학·전사체학 시장의 개요
- 아시아태평양의 공간 유전체학·전사체학 제품의 시장 점유율 : 기법별, 국가별(2023년)
- 공간 유전체학·전사체학 제품 시장 : 지역적 성장 기회
- 공간 유전체학·전사체학 제품의 시장 점유율 : 최종사용자별(2023년)
- 공간 유전체학·전사체학 서비스의 시장 점유율 : 최종사용자별(2023년)
제5장 시장의 개요
- 서론
- 시장 역학
- 고객 비즈니스에 영향을 미치는 동향/혼란
- 가격 분석
- 기구의 평균 판매 가격의 동향 : 주요 기업별(2021-2023년)
- 소모품의 평균 판매 가격의 동향 : 주요 기업별(2021-2023년)
- 주요 제품의 평균 판매 가격 : 지역별(2021-2023년)
- 공급망 분석
- 밸류체인 분석
- 에코시스템 분석
- 기술 분석
- 특허 분석
- 주요 컨퍼런스와 이벤트(2025-2026년)
- 규제 상황
- Porter's Five Forces 분석
- 주요 이해관계자와 구입 기준
- 무역 분석
- HS 코드 902790의 수입 데이터
- HS 코드 902790의 수출 데이터
- 투자와 자금조달 시나리오
- 공간 유전체학·전사체학 시장에 대한 AI/생성형 AI의 영향
제6장 공간 유전체학·전사체학 시장 : 제공별
제7장 공간 유전체학·전사체학 제품 시장 : 기법별
- 서론
- 공간 전사체학
- 면역조직화학
- 면역 형광
- 현미경 기반 RNA 이미징
- in situ 하이브리다이제이션
- LASER CAPTURE MICRODISSECTION
- RNA 시퀀싱
- 기타 공간 전사체학 기법
- 공간 유전체학
- in situ 하이브리다이제이션
- LASER CAPTURE MICRODISSECTION
- 게놈 시퀀싱
- 기타 공간 유전체학 기법
제8장 공간 유전체학·전사체학 서비스 시장 : 유형별
- 서론
- 샘플 조제 서비스
- 시퀀싱·애널리틱스 서비스
- 데이터 시각화·분석 서비스
제9장 공간 유전체학·전사체학 시장 : 용도별
- 서론
- 번역 연구
- Drug Discovery·의약품 개발
제10장 공간 유전체학·전사체학 제품 시장 : 최종사용자별
- 서론
- 제약 기업, 바이오테크놀러지 기업
- 학술연구기관
- CRO·CDMO
- 임상 진단 검사실
제11장 공간 유전체학·전사체학 서비스 시장 : 최종사용자별
- 서론
- 제약 기업, 바이오테크놀러지 기업
- 학술연구기관
- 기타 최종사용자
제12장 공간 유전체학·전사체학 시장 : 지역별
- 서론
- 북미
- 유럽
- 유럽의 거시경제 전망
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
- 아시아태평양
- 아시아태평양의 거시경제 전망
- 중국
- 일본
- 인도
- 한국
- 호주
- 기타 아시아태평양
- 라틴아메리카
- 라틴아메리카의 거시경제 전망
- 브라질
- 멕시코
- 기타 라틴아메리카
- 중동
- 아프리카
제13장 경쟁 구도
- 서론
- 주요 참여 기업의 전략/강점
- 매출 분석(2019-2023년)
- 시장 점유율 분석(2023년)
- 공간 유전체학·전사체학 제품 시장
- 공간 유전체학·전사체학 서비스 시장
- 주요 시장 기업의 순위
- 기업의 평가와 재무 지표
- 브랜드/제품의 비교
- 기업 평가 매트릭스 : 주요 기업(2023년)
- 기업 평가 매트릭스 : 스타트업/중소기업(2023년)
- 경쟁 시나리오
제14장 기업 개요
- 주요 기업
- 10X GENOMICS
- BIO-TECHNE
- NANOSTRING TECHNOLOGIES, INC.(BRUKER SPATIAL BIOLOGY, INC.)
- STANDARD BIOTOOLS
- ILLUMINA, INC.
- BIO-RAD LABORATORIES, INC.
- AKOYA BIOSCIENCES, INC.
- VISIOPHARM A/S
- DANAHER CORPORATION
- SEVEN BRIDGES GENOMICS
- REVVITY
- VIZGEN INC.
- VERACYTE, INC.
- NATERA, INC.
- MACROGEN INC.
- MILTENYI BIOTEC
- 기타 기업
- BIOMARKER TECHNOLOGIES(BMKGENE)
- ULTIVUE, INC.
- RARECYTE, INC.
- S2 GENOMICS, INC.
- ADMERA HEALTH
- SONY BIOTECHNOLOGY INC.
- CANTATA BIO
- NUCLEAI, INC.
- VISIKOL, INC.
- IONPATH, INC.
- BIOSPYDER, INC.
- SINGULAR GENOMICS SYSTEMS, INC.
- LUNAPHORE TECHNOLOGIES SA
- REBUS BIOSYSTEMS, INC.
제15장 부록
KSA
The spatial genomics & transcriptomics product market is expected to reach USD 995.7 million in 2029 from USD 554.5 million in 2024, at a CAGR of 12.4% during the forecast period.
| Scope of the Report |
|---|
| Years Considered for the Study | 2022-2029 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Units Considered | Value (USD) |
| Segments | Offering, Technique, Application, Type (Service), End User (Product), End User (Service) |
| Regions covered | North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa |
The spatial genomics and transcriptomics market is expanding under the influence of factors like new product introduction and rising acceptance of spatial genomics and transcriptomics in medication discovery and development. Nevertheless, expensive initial capital inputs and technical complexity and knowledge gap create various difficulties for the industry.
"The product segment accounted for the largest share by offering segment in the spatial genomics & transcriptomics market in 2023".
Products and services divide the spatial genomics & transcriptomics market. In 2023 the product segment held the biggest share. The growing demand for high-resolution spatial gene and protein expression data in research helps to explain the expansion of this area. The main forces behind the market expansion are the expanding uses of consumables and spatial genomics and transcriptomics in drug research and development as well as biomarketer identification. Key element driving development in this market segment is increased investments by market participants in creating various software especially for spatial analysis and introduction of new goods.
"The spatial transcriptomics technique held the highest market share of the spatial genomics and transcriptomics market by technique in 2023".
Techniques divide the spatial genomics and transcriptomics market into spatial transcriptomics and spatial genomics segments. Driven by growing acceptance of in situ sequencing technologies and more general applications in disease research, the segment of spatial transcriptomics held the biggest share of spatial genomics & transcriptomics market in 2023. Using spatial transcriptomics, one may map gene expression inside the spatial context of a tissue. Combining histology and molecular data reveals how genes are expressed in certain tissue country or region, so providing understanding of cellular organization, function, and disease progression.
"The Asia Pacific region is growing at the highest CAGR in the spatial genomics & transcriptomics market from 2024 to 2029."
The Asia Pacific is estimated to be the fastest-growing segment of the market owing to the a
increasing government efforts to rising healthcare needs, growing government investment in
biotechnology, growing demand of precision medicine, rising healthcare expenditure, growing
R&D expansion in key markets such as India, China, and Japan, and the favorable regulatory
environment in the region. However, North America held the largest share of spatial genomics & transcriptomics market in 2023.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 60% and Demand Side 40%
- By Designation: Managers - 45% CXOs and Director-level - 30%, and Executives - 25%,
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, and Middle East -5%.
List of Companies Profiled in the Report:
- NanoString Technologies, Inc. (Bruker Spatial Biology, Inc.) (US)
- 10x Genomics (US)
- Bio-Rad Laboratories, Inc. (US)
- Illumina, Inc. (US)
- Bio-Techne (US)
- Seven Bridges Genomics (US)
- Rarecyte, Inc. (US)
- Standard BioTools (US)
- Revvity (US)
- Akoya Biosciences, Inc. (US)
- Natera, Inc. (US)
- VisioPharm A/S (Switzerland)
- Danaher Corporation (US)
- Veracyte, Inc. (US)
- Biomarker Technologies (BMKGENE) (China)
- Macrogen, Inc. (South Korea)
- Miltenyi Biotec (Germany)
- Sony Biotechnology Inc. (US)
- Vizgen Inc. (US)
- BioSpyder, Inc. (US)
- Ionpath, Inc. (US)
- S2 Genomics, Inc. (US)
- Ultivue, Inc. (US)
- Admera Health (US)
- Lunaphore Technologies SA (US)
- Visikol, Inc. (US)
- Rebus Biosystems, Inc. (US)
- Singular Genomics Systems, Inc. (US)
- Cantata Bio (US)
- Nucleai, Inc. (Israel)
Research Coverage:
This research report categorizes the spatial genomics & transcriptomics market by offering (products and services), by technique (spatial transcriptomics and spatial genomics), by type (service) (sample preparation services, sequencing & analytical services, and data visualization & analysis services), by application (translational research and drug discovery & development), by end user (product) (pharmaceutical & biotechnology companies, academic & research institutes, CROs & CDMOs, and clinical diagnostic laboratories), by end user (service) (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the spatial genomics & transcriptomics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product & service portfolio, key strategies such as product & service launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the spatial genomics & transcriptomics market. Competitive analysis of top players and upcoming startups in the spatial genomics & transcriptomics market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall spatial genomics & transcriptomics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Increasing adoption of spatial genomics and transcriptomics in drug discovery and development, Introduction of novel products, Increasing pharmaceutical R&D investments and public-private funding), restraints (High initial capital investments and maintenance costs, Technical complexity and expertise gap), opportunities (Increasing use of spatial omics for biomarker identification, Increasing demand for precision medicines and targeted drug development), and challenges (Dearth of skilled professionals) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched product/services of the spatial genomics & transcriptomics market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the spatial genomics & transcriptomics market
- Competitive Assessment: NanoString Technologies, Inc. (Bruker Spatial Biology, Inc.) (US), 10x Genomics (US), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), Bio-Techne (US), Seven Bridges Genomics (US), Rarecyte, Inc. (US), Standard BioTools (US), Revvity (US), Akoya Biosciences, Inc. (US), Natera, Inc. (US), VisioPharm A/S (Switzerland), Danaher Corporation (US), Veracyte, Inc. (US), Biomarker Technologies (BMKGENE) (China), Macrogen, Inc. (South Korea), Miltenyi Biotec (Germany), Sony Biotechnology Inc. (US), Vizgen Inc. (US), BioSpyder, Inc. (US), Ionpath, Inc. (US), S2 Genomics, Inc. (US), Ultivue, Inc. (US), Admera Health (US), Lunaphore Technologies SA (US), Visikol, Inc. (US), Rebus Biosystems, Inc. (US), Singular Genomics Systems, Inc. (US), Cantata Bio (US), and Nucleai, Inc. (Israel).
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 INCLUSIONS & EXCLUSIONS
- 1.4 STUDY SCOPE
- 1.4.1 SEGMENTS AND REGIONS CONSIDERED
- 1.4.2 YEARS CONSIDERED
- 1.4.3 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES
- 1.6.1 IMPACT OF AI/GEN AI
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.1.1 Objectives of secondary research
- 2.1.2 PRIMARY DATA
- 2.1.2.1 Breakdown of primaries
- 2.1.2.2 Objectives of primary research
- 2.2 MARKET SIZE ESTIMATION
- 2.2.1 REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)
- 2.2.1.1 Insights from primary sources
- 2.2.2 SEGMENTAL MARKET ESTIMATION: TOP-DOWN APPROACH (PRODUCT)
- 2.3 GROWTH RATE PROJECTIONS
- 2.4 DATA TRIANGULATION
- 2.5 STUDY ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET OVERVIEW
- 4.2 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET SHARE, BY TECHNIQUE AND COUNTRY (2023)
- 4.3 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
- 4.4 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET SHARE, BY END USER (2023)
- 4.5 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET SHARE, BY END USER (2023)
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Increasing adoption of spatial genomics and transcriptomics in drug discovery and development
- 5.2.1.2 Introduction of novel products
- 5.2.1.3 Increasing pharmaceutical R&D investments and public-private funding
- 5.2.2 RESTRAINTS
- 5.2.2.1 High initial capital investments and maintenance costs
- 5.2.2.2 Technical complexity and expertise gap
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Increasing use of spatial omics for biomarker identification
- 5.2.3.2 Growing demand for precision medicines and targeted drug development
- 5.2.4 CHALLENGES
- 5.2.4.1 Dearth of skilled professionals
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
- 5.4 PRICING ANALYSIS
- 5.4.1 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY KEY PLAYER, 2021-2023
- 5.4.2 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY KEY PLAYER, 2021-2023
- 5.4.3 AVERAGE SELLING PRICE OF KEY PRODUCTS, BY REGION, 2021-2023
- 5.5 SUPPLY CHAIN ANALYSIS
- 5.6 VALUE CHAIN ANALYSIS
- 5.7 ECOSYSTEM ANALYSIS
- 5.8 TECHNOLOGY ANALYSIS
- 5.8.1 KEY TECHNOLOGIES
- 5.8.1.1 In-situ sequencing
- 5.8.1.2 In-situ hybridization
- 5.8.1.3 Single-cell RNA sequencing
- 5.8.2 COMPLEMENTARY TECHNOLOGIES
- 5.8.2.1 Multi-isotope imaging mass spectrometry
- 5.8.2.2 Spatial heatmap
- 5.8.2.3 Differential gene expression analysis
- 5.8.3 ADJACENT TECHNOLOGIES
- 5.8.3.1 Multi-omics
- 5.8.3.2 Metabolomics
- 5.8.3.3 Single-cell analysis
- 5.9 PATENT ANALYSIS
- 5.10 KEY CONFERENCES & EVENTS, 2025-2026
- 5.11 REGULATORY LANDSCAPE
- 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.11.2 REGULATORY FRAMEWORK
- 5.12 PORTER'S FIVE FORCES ANALYSIS
- 5.12.1 THREAT OF NEW ENTRANTS
- 5.12.2 THREAT OF SUBSTITUTES
- 5.12.3 BARGAINING POWER OF BUYERS
- 5.12.4 BARGAINING POWER OF SUPPLIERS
- 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.13.2 KEY BUYING CRITERIA, BY END USER (PRODUCT)
- 5.14 TRADE ANALYSIS
- 5.14.1 IMPORT DATA FOR HS CODE 902790
- 5.14.2 EXPORT DATA FOR HS CODE 902790
- 5.15 INVESTMENT & FUNDING SCENARIO
- 5.16 IMPACT OF AI/GEN AI ON SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET
6 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, BY OFFERING
- 6.1 INTRODUCTION
- 6.2 PRODUCTS
- 6.2.1 INSTRUMENTS & SOFTWARE
- 6.2.1.1 Instruments & software to facilitate disease research by enabling detailed spatial mapping and multi-omic analyses
- 6.2.2 CONSUMABLES
- 6.2.2.1 Better reproducible and high-quality data collection to advance spatial genomics research in oncology and precision medicine
- 6.3 SERVICES
- 6.3.1 INCREASING DEMAND FOR HIGH-QUALITY SPATIAL DATA IN PRECISION MEDICINE TO AUGMENT MARKET GROWTH
7 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET, BY TECHNIQUE
- 7.1 INTRODUCTION
- 7.2 SPATIAL TRANSCRIPTOMICS
- 7.2.1 IMMUNOHISTOCHEMISTRY
- 7.2.1.1 Increasing applications in biomarker discovery and cellular interactions within tissue architecture to drive segment
- 7.2.2 IMMUNOFLUORESCENCE
- 7.2.2.1 Advanced profiling immune-tumor microenvironments for cancer diagnosis and prognosis to propel segment growth
- 7.2.3 MICROSCOPY-BASED RNA IMAGING
- 7.2.3.1 Better insights into molecular communication within tissue architecture to augment segment growth
- 7.2.4 IN-SITU HYBRIDIZATION
- 7.2.4.1 High-throughput and 3D spatial gene expression analysis in cancer research and developmental biology to drive segment
- 7.2.5 LASER CAPTURE MICRODISSECTION
- 7.2.5.1 Analysis of gene expression data from defined cellular populations to facilitate spatial mapping within tissue sections
- 7.2.6 RNA SEQUENCING
- 7.2.6.1 In-situ RNA sequencing
- 7.2.6.1.1 Integration of ISS with bioinformatics toolkits for data analysis to facilitate interpretation of complex datasets
- 7.2.6.2 Single-cell RNA (SC-RNA) sequencing
- 7.2.6.2.1 Increasing commercial availability of scRNA-seq platforms and advancements in bioinformatics tools to drive segment
- 7.2.6.3 Other RNA sequencing
- 7.2.7 OTHER SPATIAL TRANSCRIPTOMIC TECHNIQUES
- 7.3 SPATIAL GENOMICS
- 7.3.1 IN-SITU HYBRIDIZATION
- 7.3.1.1 Demand for high-specificity detection platforms to fuel market growth
- 7.3.2 LASER CAPTURE MICRODISSECTION
- 7.3.2.1 Detailed insights into cellular mechanisms and molecular profiles within heterogeneous tissue samples to drive segment
- 7.3.3 GENOMIC SEQUENCING
- 7.3.3.1 Microdissection-based sequencing
- 7.3.3.1.1 Increased demand for precision medicines to boost segment growth
- 7.3.3.2 Chromatin accessibility sequencing
- 7.3.3.2.1 Need for insights into gene regulation and epigenetic modifications to aid segment growth
- 7.3.3.3 Other genomic sequencing
- 7.3.4 OTHER SPATIAL GENOMIC TECHNIQUES
8 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET, BY TYPE
- 8.1 INTRODUCTION
- 8.2 SAMPLE PREPARATION SERVICES
- 8.2.1 NEED FOR ACCURATE SPATIAL ANALYSIS OF GENE EXPRESSION WITHIN TISSUE SAMPLES TO SPUR MARKET GROWTH
- 8.3 SEQUENCING & ANALYTICAL SERVICES
- 8.3.1 SEQUENCING & ANALYTICAL SERVICES TO UTILIZE ADVANCED TECHNOLOGIES FOR SEQUENCING AND BIOINFORMATICS ANALYSIS
- 8.4 DATA VISUALIZATION & ANALYSIS SERVICES
- 8.4.1 INCREASED DEMAND FOR ADVANCED TOOLS FOR COMPLEX SPATIAL GENOMICS DATA INTERPRETATION TO SUPPORT MARKET GROWTH
9 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, BY APPLICATION
- 9.1 INTRODUCTION
- 9.2 TRANSLATIONAL RESEARCH
- 9.2.1 CANCER
- 9.2.1.1 Spatial genomics and transcriptomics to map precise locations of DNA and RNA within tumor tissues in cancer research
- 9.2.2 IMMUNOLOGY
- 9.2.2.1 Need for better understanding of immune cell interactions and tissue-specific immune responses to propel segment growth
- 9.2.3 NEUROSCIENCE
- 9.2.3.1 Increased focus on mapping cellular diversity for analyzing brain function and dysfunction to aid market growth
- 9.2.4 INFECTIOUS DISEASES
- 9.2.4.1 Need for enhanced understanding of pathogen-host interactions at tissue level to drive adoption
- 9.2.5 OTHER DISEASES
- 9.3 DRUG DISCOVERY & DEVELOPMENT
- 9.3.1 RISING USE OF RNA-SEQ IN DISEASE MANAGEMENT DRUG DISCOVERY TO DRIVE MARKET
10 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET, BY END USER
- 10.1 INTRODUCTION
- 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 10.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO TRANSFORM DISEASE RESEARCH AND STREAMLINE DRUG TARGET VALIDATION
- 10.3 ACADEMIC & RESEARCH INSTITUTES
- 10.3.1 FOCUS ON FOUNDATIONAL DISCOVERIES AND CELLULAR INSIGHTS ABOUT COMPLEX BIOLOGICAL SYSTEMS TO AID MARKET GROWTH
- 10.4 CROS & CDMOS
- 10.4.1 GROWING DEMAND FOR PRECISE SPATIAL MOLECULAR INSIGHTS TO PROPEL MARKET GROWTH
- 10.5 CLINICAL DIAGNOSTIC LABORATRIES
- 10.5.1 IMPROVED DIAGNOSTIC ACCURACY IN PATHOGEN DETECTION AND GENOMIC ANALYSIS TO AID MARKET GROWTH
11 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET, BY END USER
- 11.1 INTRODUCTION
- 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 11.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO OPTIMIZE BIOMARKER DEVELOPMENT AND IMPROVE CLINICAL TRIAL DESIGN
- 11.3 ACADEMIC & RESEARCH INSTITUTES
- 11.3.1 NEED FOR TOOLS FOR MAPPING CELLULAR ENVIRONMENTS AND STUDYING DISEASE MECHANISMS TO PROPEL MARKET GROWTH
- 11.4 OTHER END USERS
12 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, BY REGION
- 12.1 INTRODUCTION
- 12.2 NORTH AMERICA
- 12.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
- 12.2.2 US
- 12.2.2.1 US to dominate North American spatial genomics & transcriptomics market during forecast period
- 12.2.3 CANADA
- 12.2.3.1 Favorable government initiatives and high incidence of infectious diseases to support market growth
- 12.3 EUROPE
- 12.3.1 EUROPE: MACROECONOMIC OUTLOOK
- 12.3.2 GERMANY
- 12.3.2.1 Advanced genomics research and presence of several key companies to spur market growth
- 12.3.3 UK
- 12.3.3.1 Increasing government funding and rising demand for new diagnostic biomarkers to aid market growth
- 12.3.4 FRANCE
- 12.3.4.1 Increasing investments in life science R&D and rising number of biotech companies to propel market growth
- 12.3.5 ITALY
- 12.3.5.1 Increasing focus on neuroscience and rare disease research to augment market growth
- 12.3.6 SPAIN
- 12.3.6.1 Focus on advanced cancer research and increased need for personalized medicines to propel market growth
- 12.3.7 REST OF EUROPE
- 12.4 ASIA PACIFIC
- 12.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
- 12.4.2 CHINA
- 12.4.2.1 Increasing R&D spending by government and biopharma companies to propel market growth
- 12.4.3 JAPAN
- 12.4.3.1 Favorable government policies and high R&D funding to boost market growth
- 12.4.4 INDIA
- 12.4.4.1 Increasing collaborations between hospitals and diagnostics centers to boost market growth
- 12.4.5 SOUTH KOREA
- 12.4.5.1 Increased research on advanced precision medicines and well-established biotechnology infrastructure to aid market growth
- 12.4.6 AUSTRALIA
- 12.4.6.1 Strategic focus on advancing cancer research and precision oncology to boost market growth
- 12.4.7 REST OF ASIA PACIFIC
- 12.5 LATIN AMERICA
- 12.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
- 12.5.2 BRAZIL
- 12.5.2.1 Increasing adoption of biomarkers for drug discovery & development to drive market
- 12.5.3 MEXICO
- 12.5.3.1 Favorable funding scenario in biotechnology sector and high funding in biomanufacturing to augment market growth
- 12.5.4 REST OF LATIN AMERICA
- 12.6 MIDDLE EAST
- 12.6.1 LOWER R&D INVESTMENTS AND WEAK INFRASTRUCTURAL DEVELOPMENTS TO HINDER MARKET GROWTH
- 12.6.2 MIDDLE EAST: MACROECONOMIC OUTLOOK
- 12.7 AFRICA
- 12.7.1 INCREASING FUNDING AND PARTNERSHIPS IN RESEARCH SECTOR TO SUPPORT GROWTH OF BIOTECHNOLOGY INDUSTRY
- 12.7.2 AFRICA: MACROECONOMIC OUTLOOK
13 COMPETITIVE LANDSCAPE
- 13.1 INTRODUCTION
- 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET
- 13.3 REVENUE ANALYSIS, 2019-2023
- 13.4 MARKET SHARE ANALYSIS, 2023
- 13.4.1 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET
- 13.4.2 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET
- 13.4.3 RANKING OF KEY MARKET PLAYERS
- 13.5 COMPANY VALUATION & FINANCIAL METRICS
- 13.5.1 COMPANY VALUATION
- 13.5.2 FINANCIAL METRICS
- 13.6 BRAND/PRODUCT COMPARISON
- 13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 13.7.1 STARS
- 13.7.2 EMERGING LEADERS
- 13.7.3 PERVASIVE PLAYERS
- 13.7.4 PARTICIPANTS
- 13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
- 13.7.5.1 Company footprint
- 13.7.5.2 Region footprint
- 13.7.5.3 Offering footprint
- 13.7.5.4 Technique footprint
- 13.7.5.5 Application footprint
- 13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 13.8.1 PROGRESSIVE COMPANIES
- 13.8.2 RESPONSIVE COMPANIES
- 13.8.3 DYNAMIC COMPANIES
- 13.8.4 STARTING BLOCKS
- 13.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
- 13.8.5.1 Detailed list of key startups/SMEs
- 13.8.5.2 Competitive benchmarking of key startups/SMEs
- 13.9 COMPETITIVE SCENARIO
- 13.9.1 PRODUCT LAUNCHES
- 13.9.2 DEALS
- 13.9.3 EXPANSIONS
14 COMPANY PROFILES
- 14.1 KEY PLAYERS
- 14.1.1 10X GENOMICS
- 14.1.1.1 Business overview
- 14.1.1.2 Products/Services/Solutions offered
- 14.1.1.3 Recent developments
- 14.1.1.3.1 Product launches
- 14.1.1.3.2 Deals
- 14.1.1.3.3 Expansions
- 14.1.1.4 MnM view
- 14.1.1.4.1 Key strengths
- 14.1.1.4.2 Strategic choices
- 14.1.1.4.3 Weaknesses and competitive threats
- 14.1.2 BIO-TECHNE
- 14.1.2.1 Business overview
- 14.1.2.2 Products/Services/Solutions offered
- 14.1.2.3 Recent developments
- 14.1.2.3.1 Product launches
- 14.1.2.3.2 Deals
- 14.1.2.3.3 Expansions
- 14.1.2.4 MnM view
- 14.1.2.4.1 Key strengths
- 14.1.2.4.2 Strategic choices
- 14.1.2.4.3 Weaknesses and competitive threats
- 14.1.3 NANOSTRING TECHNOLOGIES, INC. (BRUKER SPATIAL BIOLOGY, INC.)
- 14.1.3.1 Business overview
- 14.1.3.2 Products/Services/Solutions offered
- 14.1.3.3 Recent developments
- 14.1.3.3.1 Product launches
- 14.1.3.3.2 Deals
- 14.1.3.4 MnM view
- 14.1.3.4.1 Key strengths
- 14.1.3.4.2 Strategic choices
- 14.1.3.4.3 Weaknesses and competitive threats
- 14.1.4 STANDARD BIOTOOLS
- 14.1.4.1 Business overview
- 14.1.4.2 Products/Services/Solutions offered
- 14.1.4.3 Recent developments
- 14.1.4.3.1 Product launches
- 14.1.4.3.2 Deals
- 14.1.4.4 MnM view
- 14.1.4.4.1 Key strengths
- 14.1.4.4.2 Strategic choices
- 14.1.4.4.3 Weaknesses and competitive threats
- 14.1.5 ILLUMINA, INC.
- 14.1.5.1 Business overview
- 14.1.5.2 Products/Services/Solutions offered
- 14.1.5.3 Recent developments
- 14.1.5.3.1 Product launches
- 14.1.5.3.2 Deals
- 14.1.5.4 MnM view
- 14.1.5.4.1 Key strengths
- 14.1.5.4.2 Strategic choices
- 14.1.5.4.3 Weaknesses and competitive threats
- 14.1.6 BIO-RAD LABORATORIES, INC.
- 14.1.6.1 Business overview
- 14.1.6.2 Products/Services/Solutions offered
- 14.1.6.3 Recent developments
- 14.1.6.3.1 Product launches
- 14.1.6.3.2 Deals
- 14.1.7 AKOYA BIOSCIENCES, INC.
- 14.1.7.1 Business overview
- 14.1.7.2 Products/Services/Solutions offered
- 14.1.7.3 Recent developments
- 14.1.7.3.1 Product launches
- 14.1.7.3.2 Deals
- 14.1.7.3.3 Expansions
- 14.1.8 VISIOPHARM A/S
- 14.1.8.1 Business overview
- 14.1.8.2 Products/Services/Solutions offered
- 14.1.8.3 Recent developments
- 14.1.8.3.1 Product launches
- 14.1.8.3.2 Deals
- 14.1.9 DANAHER CORPORATION
- 14.1.9.1 Business overview
- 14.1.9.2 Products/Services/Solutions offered
- 14.1.9.3 Recent developments
- 14.1.10 SEVEN BRIDGES GENOMICS
- 14.1.10.1 Business overview
- 14.1.10.2 Products/Services/Solutions offered
- 14.1.10.3 Recent developments
- 14.1.11 REVVITY
- 14.1.11.1 Business overview
- 14.1.11.2 Products/Services/Solutions offered
- 14.1.11.3 Recent developments
- 14.1.11.3.1 Product launches & approvals
- 14.1.11.3.2 Deals
- 14.1.12 VIZGEN INC.
- 14.1.12.1 Business overview
- 14.1.12.2 Products/Services/Solutions offered
- 14.1.12.3 Recent developments
- 14.1.12.3.1 Product launches
- 14.1.12.3.2 Deals
- 14.1.13 VERACYTE, INC.
- 14.1.13.1 Business overview
- 14.1.13.2 Products/Services/Solutions offered
- 14.1.14 NATERA, INC.
- 14.1.14.1 Business overview
- 14.1.14.2 Products/Services/Solutions offered
- 14.1.14.3 Recent developments
- 14.1.14.3.1 Product launches
- 14.1.14.3.2 Expansions
- 14.1.15 MACROGEN INC.
- 14.1.15.1 Business overview
- 14.1.15.2 Products/Services/Solutions offered
- 14.1.15.3 Recent developments
- 14.1.16 MILTENYI BIOTEC
- 14.1.16.1 Business overview
- 14.1.16.2 Products/Services/Solutions offered
- 14.1.16.3 Recent developments
- 14.2 OTHER PLAYERS
- 14.2.1 BIOMARKER TECHNOLOGIES (BMKGENE)
- 14.2.2 ULTIVUE, INC.
- 14.2.3 RARECYTE, INC.
- 14.2.4 S2 GENOMICS, INC.
- 14.2.5 ADMERA HEALTH
- 14.2.6 SONY BIOTECHNOLOGY INC.
- 14.2.7 CANTATA BIO
- 14.2.8 NUCLEAI, INC.
- 14.2.9 VISIKOL, INC.
- 14.2.10 IONPATH, INC.
- 14.2.11 BIOSPYDER, INC.
- 14.2.12 SINGULAR GENOMICS SYSTEMS, INC.
- 14.2.13 LUNAPHORE TECHNOLOGIES SA
- 14.2.14 REBUS BIOSYSTEMS, INC.
15 APPENDIX
- 15.1 DISCUSSION GUIDE
- 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 15.3 CUSTOMIZATION OPTIONS
- 15.4 RELATED REPORTS
- 15.5 AUTHOR DETAILS
